SCHEMBL21712431

SCHEMBL21712431

CCCCCCCCCCCCCCCCCC(=O)NCCCOc1cccc2nc(N)c3nc(COCC)n(C)c3c12

nearest known ligand 0.50

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 17/20 0.50
TLR8 Q9NR97 14/20 0.50
CNR1 P21554 2/20 0.40
CNR2 P34972 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30662193 1.00 TLR7 (0.50) TLR7TLR8CNR1CNR2
SCHEMBL30662194 1.00 TLR7 (0.50) TLR7TLR8CNR1CNR2
SCHEMBL21712342 1.00 TLR7 (0.50) TLR7TLR8CNR1CNR2
SCHEMBL30662188 0.98 TLR7 (0.51) TLR7TLR8CNR1CNR2
SCHEMBL21712318 0.98 TLR7 (0.51) TLR7TLR8CNR1CNR2
SCHEMBL21712410 0.98 TLR7 (0.51) TLR7TLR8CNR1CNR2
SCHEMBL26859450 0.89 TLR7 (0.46) TLR7TLR8
SCHEMBL30662177 0.88 TLR7 (0.53) TLR7TLR8
SCHEMBL21712415 0.88 TLR7 (0.53) TLR7TLR8
SCHEMBL21712441 0.86 TLR7 (0.52) TLR7TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615539-B1 2-AMINO-QUINOLINE DERIVATIVES BIRDIE BIOPHARMACEUTICALS INC (KY) 2023-08-09 EP claimed
US-11053240-B2 2-amino-quinoline derivatives BIRDIE BIOPHARMACEUTICALS, INC. (KY) 2021-07-06 US claimed
CN-110637018-A 2-amino-quinoline derivatives 博笛生物科技有限公司 2019-12-31 CN claimed
US-11834448-B2 2-amino-quinoline derivatives BIRDIE BIOPHARMACEUTICALS, INC. (KY) 2023-12-05 US disclosed
US-11834448-B2 2-amino-quinoline derivatives BIRDIE BIOPHARMACEUTICALS, INC. (KY) 2023-12-05 US disclosed
EP-3615539-B1 2-AMINO-QUINOLINE DERIVATIVES BIRDIE BIOPHARMACEUTICALS INC (KY) 2023-08-09 EP disclosed
US-11053240-B2 2-amino-quinoline derivatives BIRDIE BIOPHARMACEUTICALS, INC. (KY) 2021-07-06 US disclosed
US-20200055851-A1 2-AMINO-QUINOLINE DERIVATIVES BIRDIE BIOPHARMACEUTICALS, INC. (KY) 2020-02-20 US disclosed
CN-110637018-A 2-amino-quinoline derivatives 博笛生物科技有限公司 2019-12-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11053240-B2 2-amino-quinoline derivatives TLR7, TLR8, TLR1 TLR7 1/4885TLR8 2/4885CNR1 289/4885
US-20200055851-A1 2-AMINO-QUINOLINE DERIVATIVES TLR7, TLR8, TLR1 TLR7 1/4885TLR8 2/4885CNR1 289/4885
US-11834448-B2 2-amino-quinoline derivatives TLR7, TLR8, TLR1 TLR7 1/4885TLR8 2/4885CNR1 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.